Acute Ischemic Stroke Therapy Overview.
The treatment of acute ischemic stroke has undergone dramatic changes recently subsequent to the demonstrated efficacy of intra-arterial (IA) device-based therapy in multiple trials. The selection of patients for both intravenous and IA therapy is based on timely imaging with either computed tomography or magnetic resonance imaging, and if IA therapy is considered noninvasive, angiography with one of these modalities is necessary to document a large-vessel occlusion amenable for intervention. More advanced computed tomography and magnetic resonance imaging studies are available that can be used to identify a small ischemic core and ischemic penumbra, and this information will contribute increasingly in treatment decisions as the therapeutic time window is lengthened. Intravenous thrombolysis with tissue-type plasminogen activator remains the mainstay of acute stroke therapy within the initial 4.5 hours after stroke onset, despite the lack of Food and Drug Administration approval in the 3- to 4.5-hour time window. In patients with proximal, large-vessel occlusions, IA device-based treatment should be initiated in patients with small/moderate-sized ischemic cores who can be treated within 6 hours of stroke onset. The organization and implementation of regional stroke care systems will be needed to treat as many eligible patients as expeditiously as possible. Novel treatment paradigms can be envisioned combining neuroprotection with IA device treatment to potentially increase the number of patients who can be treated despite long transport times and to ameliorate the consequences of reperfusion injury. Acute stroke treatment has entered a golden age, and many additional advances can be anticipated.
From the Department of Neurology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA.
Luciana
L
Catanese
From the Department of Neurology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA.
Joseph
J
Tarsia
From the Department of Neurology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA. mfisher5@bidmc.harvard.edu.
Marc
M
Fisher
D002545:Brain Ischemia / Q000000981:diagnostic imaging* / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods; D057510:Endovascular Procedures / Q000379:methods; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D020521:Stroke / Q000000981:diagnostic imaging* / Q000628:therapy*; D015912:Thrombolytic Therapy / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator
imaging; intervention; stroke; therapy; thrombolysis